

## Special Issue

# Cancer Immunotherapy as Part of Precision Clinical Medicine

### Message from the Guest Editors

In the last decade, the significant expansion of therapeutic options has transformed the management of almost all forms of cancer. Immunotherapy refers to a novel approach that enables the human immune system to recognize self and non-self and activate an antitumor response in a more precise way. Recent advances in immunotherapy have been at the forefront of this revolution, leading to viable therapeutic options in previously minimally responsive cancers such as gastric and pancreatic cancer. Therefore, this Special Issue welcomes the submission of papers that explore the advancement of exploration, enhance our understanding of the tumor microenvironment as a predictive and prognostic marker and provide an in-depth understanding of the genomics of different cancer types in order to develop more precise and effective immunotherapy for cancer.

### Guest Editors

Prof. Dr. Peter Lang

Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany

Dr. Christo Kole

1. Cardiology Department, Sismanogleio General Hospital of Attica, Marousi, Greece
2. Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece

### Deadline for manuscript submissions

10 October 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/220796](https://mdpi.com/si/220796)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)